Microbiology

  1. Engineered human mesenchymal stem cells as new vaccine platform for COVID-19

    1. Junhua Liu
    2. Huping Jiao
    3. Xiushan Yin

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  2. Rapid Inactivation of SARS-CoV-2 by Silicon Nitride, Copper, and Aluminum Nitride

    1. Giuseppe Pezzotti
    2. Eriko Ohgitani
    3. Masaharu Shin-Ya
    4. Tetsuya Adachi
    5. Elia Marin
    6. Francesco Boschetto
    7. Wenliang Zhu
    8. Osam Mazda

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  3. Proteotyping SARS-CoV-2 virus from nasopharyngeal swabs: a proof-of-concept focused on a 3 min mass spectrometry window

    1. Duarte Gouveia
    2. Guylaine Miotello
    3. Fabrice Gallais
    4. Jean-Charles Gaillard
    5. Stéphanie Debroas
    6. Laurent Bellanger
    7. Jean-Philippe Lavigne
    8. Albert Sotto
    9. Lucia Grenga
    10. Olivier Pible
    11. Jean Armengaud

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  4. Identification of a critical horseshoe-shaped region in the nsp5 (Mpro, 3CLpro) protease interdomain loop (IDL) of coronavirus mouse hepatitis virus (MHV)

    1. Benjamin C. Nick
    2. Mansi C. Pandya
    3. Xiaotao Lu
    4. Megan E. Franke
    5. Sean M. Callahan
    6. Emily F. Hasik
    7. Sean T. Berthrong
    8. Mark R. Denison
    9. Christopher C. Stobart

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  5. Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2

    1. Mark Dittmar
    2. Jae Seung Lee
    3. Kanupriya Whig
    4. Elisha Segrist
    5. Minghua Li
    6. Kellie Jurado
    7. Kirandeep Samby
    8. Holly Ramage
    9. David Schultz
    10. Sara Cherry

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  6. Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies

    1. Aurelie Velay
    2. Floriane Gallais
    3. Ilies Benotmane
    4. Marie Josée Wendling
    5. François Danion
    6. Olivier Collange
    7. Jérôme De Sèze
    8. Catherine Schmidt-Mutter
    9. Francis Schneider
    10. Pascal Bilbault
    11. Ferhat Meziani
    12. Samira Fafi-Kremer

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  7. Variant analysis of SARS-CoV-2 strains in Middle Eastern countries

    1. Khalid Mubarak Bindayna
    2. Shane Crinion

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  8. Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19

    1. Nirmitee Mulgaonkar
    2. Haoqi Wang
    3. Samavath Mallawarachchi
    4. Sandun Fernando
    5. Byron Martina
    6. Daniel Ruzek

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  9. Polymorphism and Selection Pressure of SARS-CoV-2 Vaccine and Diagnostic Antigens: Implications for Immune Evasion and Serologic Diagnostic Performance

    1. Eric Dumonteil
    2. Claudia Herrera

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  10. Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike

    1. Lihong Liu
    2. Pengfei Wang
    3. Manoj S. Nair
    4. Jian Yu
    5. Micah Rapp
    6. Qian Wang
    7. Yang Luo
    8. Jasper F-W. Chan
    9. Vincent Sahi
    10. Amir Figueroa
    11. Xinzheng V. Guo
    12. Gabriele Cerutti
    13. Jude Bimela
    14. Jason Gorman
    15. Tongqing Zhou
    16. Zhiwei Chen
    17. Kwok-Yung Yuen
    18. Peter D. Kwong
    19. Joseph G. Sodroski
    20. Michael T. Yin
    21. Zizhang Sheng
    22. Yaoxing Huang
    23. Lawrence Shapiro
    24. David D. Ho

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity
Previous Page 56 of 252 Next